Hypothesis

Emodin selectively eliminates senescent microglia by concurrently inhibiting EGFR signaling and CDK2 activity, which shifts the senescence-associated secretory phenotype (SASP) from pro‑inflammatory to pro‑apoptotic and triggers mitochondrial apoptosis through p53‑dependent ROS accumulation.

Mechanistic Rationale

Emodin suppresses EGFR‑driven MAPK activation, reducing M1 macrophage polarization [2]. In senescent cells, EGFR signaling sustains CDK2‑cyclin‑A complexes that maintain the SASP via NF‑κB and STAT3 [1,3]. By blocking EGFR, emodin lowers STAT3 phosphorylation, a known resistance node to EGFR inhibition [3]. Simultaneously, emodin downregulates cyclin‑A and CDK2, causing S/G2‑M arrest and upregulating p53, p21, Bax and cleaved caspase‑3 [4]. In senescent microglia, persistent DNA damage keeps p53 active; further CDK2 inhibition prevents phosphorylation‑mediated p53 degradation, stabilizing p53 and promoting transcription of pro‑apoptotic BAX and PUMA. The combined loss of EGFR‑STAT3 survival signaling and CDK2‑mediated p53 turnover shifts the balance toward mitochondrial outer membrane permeabilization, releasing cytochrome c and activating caspase‑3. Concurrently, emodin’s inhibition of JNK and p38 MAPK reduces stress‑induced SASP components, while NF‑κB blockade lowers TNF‑α, IL‑1β, IL‑6 output, remodeling the secretome toward a less pathogenic profile.

Testable Predictions

1. Low‑dose emodin (0.5‑5 µM) will reduce viability of irradiated or oncogene‑induced senescent microglia >50 % while sparing proliferating microglia (<15 % loss) and quiescent microglia (<10 % loss).
2. Senescent microglia treated with emodin will show decreased p‑STAT3 and p‑ERK1/2, increased nuclear p53, elevated Bax/Bcl‑2 ratio, and cleaved caspase‑3 versus untreated senescent controls.
3. The senolytic effect will be abolished by ectopic CDK2 overexpression or EGFR‑L858R constitutively active mutant, rescuing viability and SASP levels.
4. SASP profiling will reveal a shift from high IL‑6, IL‑1β, TNF‑α to increased IFN‑β and reduced MCP‑1, indicating reprogramming rather than mere suppression.

Experimental Design

• Cell models: Primary mouse microglia induced senescent by 10 Gy IR or RAS^V12 lentivirus; proliferating microglia cultured with CSF‑1; quiescent microglia serum‑starved 24 h.
• Treatment: Emodin dose‑response (0.1‑10 µM) for 48 h; include vehicle control and navitoclax as positive senolytic control.
• Readouts: Viability (CellTiter‑Glo), SA‑β‑gal staining, flow cytometry for Annexin V/7‑AAD, Western blot for p‑EGFR, p‑ERK, p‑STAT3, cyclin‑A, CDK2, p53, Bax, cleaved caspase‑3. Secretome measured by Luminex panel (IL‑1β, IL‑6, TNF‑α, IFN‑β, MCP‑1).
• Rescue: Transduce senescent microglia with CDK2‑WT or EGFR‑L858R prior to emodin; assess viability and SASP.
• Statistical: n = 3 biological replicates, ANOVA with Tukey post‑hoc; significance set at p < 0.05.
• Falsifiability: If emodin kills proliferating or quiescent microglia at similar rates to senescent cells, or if CDK2/EGFR rescue does not restore viability, the hypothesis is refuted.